RxDoctor Payments Data

Tania Gonzalez Santiago, MD

Dermatopathology · Caguas, PRNPI 1952539223

Payments from drug & device makers

$487,915in general payments, 2019–2025

Across 377 payments — averaging $1294.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$287K
  • Sanofi$111K
  • Lilly USA, LLC$80K
  • Eli Lilly$8K
  • Revance Therapeutics, Inc.$917
  • Regeneron Healthcare Solutions, Inc.$422
  • plus $1K from 9 others
$5,950in research payments, 2019–2025

Across 18 payments — averaging $330.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$6K

What the payments were for

  • Consulting fees$6500%
  • Speaking & faculty fees$180,71090%
  • Travel & lodging$13,4827%
  • Food & beverage$6,6763%
  • Education$3740%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)80$287,431
Sanofi91$110,538
Lilly USA, LLC127$79,753
Eli Lilly19$7,601
Revance Therapeutics, Inc.9$917
Regeneron Healthcare Solutions, Inc.6$422
Johnson & Johnson(2 entities)11$420
Sanofi-aventis U.S. LLC2$184
Eli Lilly Export S.A. Puerto Rico Branch12$182
PBG Puerto Rico LLC7$167
E.r. Squibb & Sons, L.L.C.6$146
Novartis2$54
Incyte Corporation2$49
Amgen2$37
Strata Skin Sciences, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few dermatopathology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$69,159
Medicare patients
352
Services billed
903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab159$657,962
Skyrizi PenRisankizumab-Rzaa18$377,092
Taltz AutoinjectorIxekizumab32$217,470
OtezlaApremilast14$69,448
OlumiantBaricitinib12$58,178
Triamcinolone Acetonide305$6,070
Ketoconazole258$5,619
Betamethasone Dipropionate97$5,459
Fluocinonide118$4,121
Metronidazole64$3,571
Tacrolimus26$3,562
Dutasteride97$3,357
Desonide34$2,466
Clindamycin Phosphate36$2,080
Tretinoin24$2,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$37$69,44814 claims
Lilly USA, LLCOlumiant$79,753$58,17812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few dermatopathology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other dermatopathology in Caguas

Where these figures come from

Is this you, or does something look wrong? →